Shs · CUSIP 337185102 · who reports it, how much, and how much it matters to them
18 of the 720 hedge fund managers we track reported shares of First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX) on Form 13F for 30 June 2026. Between them they reported USD 165m. The largest position belongs to ECOR1 Capital, at USD 64m. The manager with the most riding on it is Ally Bridge Group (Ny), where it is 5.1% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | ECOR1 Capital3 funds on PPLI.com | USD 64m | 3.1% |
| 2 | 683 Capital Management2 funds on PPLI.com | USD 15m | 0.7% |
| 3 | Adage Capital Management1 fund on PPLI.com | USD 15m | 0.0% |
| 4 | Balyasny Asset Management25 funds on PPLI.com | USD 14m | 0.0% |
| 5 | Palo Alto Investors6 funds on PPLI.com | USD 12m | 1.7% |
| 6 | Sofinnova Investments1 fund on PPLI.com | USD 11m | 0.6% |
| 7 | POINT72 Asset Management17 funds on PPLI.com | USD 8.2m | 0.0% |
| 8 | Ally Bridge Group (Ny)3 funds on PPLI.com | USD 5.7m | 5.1% |
| 9 | Apis Capital Advisors4 funds on PPLI.com | USD 4.5m | 0.4% |
| 10 | Citadel Advisors32 funds on PPLI.com | USD 3.4m | 0.0% |
| 11 | Marshall Wace LLP84 funds on PPLI.com | USD 3.3m | 0.0% |
| 12 | D. E. Shaw & Co.15 funds on PPLI.com | USD 2.6m | 0.0% |
| 13 | Jain Global1 fund on PPLI.com | USD 2m | 0.0% |
| 14 | CRCM3 funds on PPLI.com | USD 1.4m | 0.5% |
| 15 | J. Goldman & Co.1 fund on PPLI.com | USD 943,000 | 0.0% |
| 16 | Sphera Funds Management1 fund on PPLI.com | USD 561,000 | 0.1% |
| 17 | Boothbay Fund Management2 funds on PPLI.com | USD 264,000 | 0.0% |
| 18 | Persistent Asset Partners10 funds on PPLI.com | USD 159,000 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Ally Bridge Group (Ny) | USD 5.7m | 5.1% |
| 2 | ECOR1 Capital | USD 64m | 3.1% |
| 3 | Palo Alto Investors | USD 12m | 1.7% |
| 4 | 683 Capital Management | USD 15m | 0.7% |
| 5 | Sofinnova Investments | USD 11m | 0.6% |
| 6 | CRCM | USD 1.4m | 0.5% |
| 7 | Apis Capital Advisors | USD 4.5m | 0.4% |
| 8 | Sphera Funds Management | USD 561,000 | 0.1% |
| 9 | Persistent Asset Partners | USD 159,000 | 0.0% |
| 10 | J. Goldman & Co. | USD 943,000 | 0.0% |
First Tracks Biotherapeutics, Inc. trades under the symbol TRAX on the Nasdaq. Its CUSIP, the code used on Form 13F, is 337185102.
18 of the 720 hedge fund managers PPLI.com tracks reported First Tracks Biotherapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by ECOR1 Capital (USD 64m), 683 Capital Management (USD 15m), Adage Capital Management (USD 15m), Balyasny Asset Management (USD 14m) and Palo Alto Investors (USD 12m).
18 managers in our coverage reported it, and between them they run 211 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Ally Bridge Group (Ny), where the position was 5.1% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with First Tracks Biotherapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.